ClinicalTrials.gg
RecruitingNCT07519330Updated Jun 15, 2026

Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

A Phase 2 interventional study of HH-006 in Chronic Hepatitis B Virus Infection, sponsored by Huahui Health. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Huahui Health · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
232nd of 273
45 · median 120
Started
2026
with 26 others
Phase 2
72 of 375
15 open now
Primary completion
2028-02
later than 87 of 109 live
Registered
353rd of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 232nd largest by planned enrollment of the 273 interventional ones that give a count, is one of 27 that started in 2026, is one of 72 in phase 2, reaches primary completion later than 87 of the 109 other live ones, and was the 353rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

83 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks. All treated patients will also undergo a follow-up period after last study drug treatment.

Read the detailed description

This is a multicenter, open-label Phase II clinical study, It aims to evaluate the efficacy, safety, and tolerability of HH-006 in untreated HBeAg-positive/negative chronic HBV infected individuals and those with HBeAg-negative chronic HBV infection who have been treated with NAs for more than one year.

Study participants will undergo various screening examinations as per the protocol before enrollment. Eligible participants will be assigned to Cohort 1, Cohort 2, or Cohort 3 according to different inclusion and exclusion criteria (see Inclusion/Exclusion Criteria for details). Upon entering the study, participants in all cohorts will start a 4-week loading dose period of HH-006 480 mg QW, followed by HH-006 240 mg QW for 44 weeks. Participants in Cohort 3 will continue their pre-existing NAs therapy after enrollment. Evaluations will include changes in HBsAg/HBV DNA/ALT and safety.

03

Conditions studied

  • Chronic Hepatitis B Virus Infection

Browse trials for

Keywords

  • chronic hepatitis B virus infection
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: male or female; Age: 18 to 45 years old (inclusive);
  • Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and (BMI): 18 kg/m² ≤ BMI ≤ 28 kg/m²;
  • and/or HBV DNA positivity for more than 6 months (including 6 months), or previous liver results indicating chronic hepatitis B, or negative for anti-HBc IgM;
  • Virological and liver function indicators at screening:

Cohort 1: HBeAg-positive, 2000 IU/mL ≤ HBsAg ≤ 100,000 IU/mL, HBV DNA > 105 IU/mL, 2 × (ULN) ≤ ≤ 8 × ULN; Cohort 2: HBeAg-negative, 100 IU/mL ≤ HBsAg ≤ 3000 IU/mL, 20 IU/mL \< HBV DNA ≤ 2000 IU/mL, ALT ≤ 5 × ULN; Cohort 3: HBeAg-negative, 100 IU/mL ≤ HBsAg ≤ 3000 IU/mL, HBV DNA ≤ 100 IU/mL, ALT ≤ 2 × ULN;

  • Previous antiviral treatment:

Cohort 1 and Cohort 2: No interferon antiviral treatment within the past 1 year, and no nucleos(t)ide analogue (NA) treatment within the 6 months prior to screening; Cohort 3: No interferon antiviral treatment within the past 1 year; received only nucleos(t)ide analogue monotherapy for at least one year;

  • Fully understand the study content, procedures, and possible adverse reactions, and sign the written form (ICF);
  • Able to communicate effectively with the investigator and complete the study in accordance with the study requirements;
  • Male subjects who have not undergone sterilization and female subjects who have been for less than two years must agree to take adequate and effective measure from screening until the last follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Co-infected with , syphilis, or (HIV);
  • At screening: total ≥ 3 × and direct bilirubin (DBil) > 1 × ULN; \< 100 g/L; count \< 100,000/mm³ (100 × 109/L); \< 1,500/mm³ (1.5 × 109/L); serum albumin \< 35 g/L; international normalized ratio (INR) > 1.3; (HbA1c) ≥ 7%; estimated (eGFR) (MDRD formula) \< 60 mL/min/1.73 m² (Appendix 2 MDRD calculation formula);
  • (ECG) abnormalities (e.g., > 450 ms in males, > 470 ms in females, severe arrhythmias such as torsade de pointes, paroxysmal ventricular tachycardia, symptomatic atrial fibrillation/flutter requiring emergency treatment, complete atrioventricular block); poorly controlled or hypertension (e.g., systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg after medication use, etc.);
  • Concurrent clinically significant other liver diseases, including but not limited to: moderate or severe fatty liver, alcoholic liver disease, liver disease, hereditary metabolic liver disease, drug-induced liver injury, etc.;
  • History of progressive hepatic fibrosis or cirrhosis at any time prior to or during screening;
  • Current or prior history of hepatic decompensation manifestations, including but not limited to: ascites, hepatic encephalopathy, esophageal and gastric variceal bleeding, hepatorenal syndrome, etc.;
  • Previous history of hepatocellular carcinoma, or at screening: serum alpha-fetoprotein (AFP) ≥ 50 ng/mL; or liver ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) findings suggestive of possible hepatocellular carcinoma;
  • Concurrent severe diseases or clinical conditions in other systems that, in the investigator's judgment, make the participant unsuitable for inclusion in this study:

    1. Circulatory system diseases: e.g., unstable angina, myocardial infarction, congestive heart failure, etc.;
    2. Respiratory system diseases: e.g., severe , etc.;
    3. Primary or secondary kidney diseases (e.g., chronic renal decompensation, renal diseases secondary to diabetes, hypertension, vascular diseases, etc.);
    4. Endocrine system diseases: e.g., poorly controlled diabetes or thyroid diseases, etc.;
    5. Autoimmune diseases: e.g., systemic lupus erythematosus, primary immune thrombocytopenia, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, autoimmune hemolytic anemia, severe psoriasis, etc.;
    6. Neuropsychiatric disorders: e.g., epilepsy, schizophrenia, depression, etc.;
    7. Malignant tumors;
  • Lactating women or those with a positive pregnancy test;
  • Persistent alcohol consumption (average daily intake > 40 g alcohol for males, > 20 g alcohol for females) or illicit drug abuse within 6 months prior to screening (including the screening period);
  • Participation in any clinical trial of a drug (except for those who did not receive the product) or medical device (except for non-invasive medical devices) within 3 months prior to screening;
  • Major trauma or major surgery within the past three months;
  • History of allergy to HH-003, HH-006, or polysorbate 80;
  • In the investigator's judgment, unsuitability for participation in this study, or close relationship with the study site: e.g., immediate family members of the investigator, or affiliated personnel (e.g., site staff or students).
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    HH-006 Cohort 1

    untreated HBeAg-positive chronic HBV infected participants will receive HH-006

    Biological: HH-006

  • Experimental
    HH-006 Cohort 2

    untreated HBeAg-negative chronic HBV infected participants will receive HH-006

    Biological: HH-006

  • Experimental
    HH-006 Cohort 3

    participants with HBeAg-negative chronic HBV infection who have been treated with NAs for more than one year will receive HH-006

    Biological: HH-006

Interventions

  • BiologicalHH-006

    HH-006 480 mg SC injection every one week for 4 weeks and followed by 240 mg QW for 44 weeks

06

What researchers measure

Primary outcomes

  1. HBsAg change from baseline

    value of HBsAg change from baseline

    Time frame: week 24

Secondary outcomes

  1. HBsAg change from baseline

    value of HBsAg change from baseline

    Time frame: week 12, week 48 of treatment and week 24 of follow up

  2. proportion of HBsAg loss

    number of participants with HBsAg loss

    Time frame: week 24, week 48 of treatment and week 24 of follow up

  3. HBsAg change from baseline

    value of HBsAg change from baseline

    Time frame: up to 72 weeks

  4. cohort 1and cohort 2: proportion of HBV DNA decreasing more than 1 log10/mL

    number of participants with HBV DNA decreasing more than 1 log10/mL

    Time frame: week 12, week 24, week 48 of treatment and week 24 of follow up

  5. proportion of HBV DNA < LLOQ

    number of participants with HBV DNA \< LLOQ

    Time frame: week 12, week 24, week 48 of treatment and week 24 of follow up

  6. HBV DNA change from baseline

    value of HBV DNA change from baseline

    Time frame: up to 72 weeks

  7. proportion of ALT normalization

    number of participants with ALT normalization

    Time frame: week 12, week 24, week 48 of treatment and week 24 of follow up

  8. ALT change from baseline

    value of ALT change from baseline

    Time frame: up to 72 weeks

  9. proportion of HBsAg seroconversion

    number of participants with HBsAg seroconversion

    Time frame: week 12, week 24, week 48 of treatment and week 24 of follow up

  10. cohort1: proportion of HBeAg seroconversion

    number of participants with HBeAg seroconversion

    Time frame: week 12, week 24, week 48 of treatment and week 24 of follow up

  11. cohort1: HBeAg change from baseline

    value of HBeAg change from baseline

    Time frame: up to 72 weeks

  12. LSM change from baseline

    value of LSM change from baseline

    Time frame: week 24, week 48 of treatment and week 24 of follow up

  13. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  14. Maximum Plasma Concentration (Cmax)

    Cmax of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  15. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  16. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  17. Apparent Plasma Clearance (CL/F)

    CL/F of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  18. Apparent volume of distribution (Vd/F)

    Vd/F of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  19. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: up to 72 weeks

  20. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.

    Time frame: up to 72 weeks follow-up

  21. Titers of Anti-drug Antibody (ADA)

    ADA analysis of HH-006

    Time frame: up to 72 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 21 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
May 14, 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Mar 22, 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07519330
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
May 14, 2026
Primary completion
Feb 28, 2028 (estimated)
Completion
Mar 22, 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Xiaoping Chen PM
Contact
chenxiaoping@hhhbio.com
+86 18518676059

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HH-006

Start the discussion